CytomX Therapeutics, Inc. (CTMX) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
CTMX Insider Trading Activity
CTMX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $82,825 | 10 | 100 |
Related Transactions
| Chu Yu-Waye | Chief Medical Officer | 0 | $0 | 1 | $2,411 | $-2,411 |
| Landau Jeffrey B | Chief Business Officer | 0 | $0 | 1 | $5,139 | $-5,139 |
| Ogden Christopher | Chief Financial Officer | 0 | $0 | 2 | $7,561 | $-7,561 |
| ROWLAND LLOYD A | General Counsel | 0 | $0 | 2 | $11,250 | $-11,250 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 0 | $0 | 2 | $16,827 | $-16,827 |
| McCarthy Sean A. | CEO | 0 | $0 | 2 | $39,638 | $-39,638 |
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Insider Activity of CytomX Therapeutics, Inc.
Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $82,825 worth of CytomX Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $360,854 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.
List of Insider Buy and Sell Transactions, CytomX Therapeutics, Inc.
| 2025-03-18 | Sale | McCarthy Sean A. | CEO | 37,656 0.0466% | $0.60 | $22,556 | +10.69% | |
| 2025-03-18 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 19,512 0.0242% | $0.60 | $11,688 | +10.69% | |
| 2025-03-18 | Sale | Ogden Christopher | Chief Financial Officer | 8,551 0.0106% | $0.60 | $5,122 | +10.69% | |
| 2025-03-18 | Sale | Chu Yu-Waye | Chief Medical Officer | 4,025 0.005% | $0.60 | $2,411 | +10.69% | |
| 2025-03-18 | Sale | ROWLAND LLOYD A | General Counsel | 10,203 0.0126% | $0.60 | $6,112 | +10.69% | |
| 2024-08-20 | Sale | McCarthy Sean A. | CEO | 13,898 0.0176% | $1.23 | $17,082 | -19.44% | |
| 2024-08-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,181 0.0053% | $1.23 | $5,139 | -19.44% | |
| 2024-08-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,181 0.0053% | $1.23 | $5,139 | -19.44% | |
| 2024-08-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,181 0.0053% | $1.23 | $5,139 | -19.44% | |
| 2024-08-20 | Sale | Ogden Christopher | Chief Financial Officer | 1,984 0.0025% | $1.23 | $2,439 | -19.44% | |
| 2024-03-19 | Sale | McCarthy Sean A. | CEO | 20,223 0.0286% | $2.09 | $42,175 | -45.64% | |
| 2024-03-19 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 12,795 0.0181% | $2.09 | $26,684 | -45.64% | |
| 2024-03-19 | Sale | ROWLAND LLOYD A | General Counsel | 5,268 0.0074% | $2.09 | $10,986 | -45.64% | |
| 2024-03-19 | Sale | Landau Jeffrey B | Chief Business Officer | 6,562 0.0093% | $2.09 | $13,685 | -45.64% | |
| 2024-03-19 | Sale | Ogden Christopher | SVP, Finance and Accounting | 2,971 0.0042% | $2.09 | $6,196 | -45.64% | |
| 2023-12-20 | Sale | McCarthy Sean A. | CEO | 13,551 0.0208% | $1.38 | $18,710 | +5.60% | |
| 2023-12-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,077 0.0063% | $1.38 | $5,628 | +5.60% | |
| 2023-12-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,077 0.0063% | $1.38 | $5,629 | +5.60% | |
| 2023-12-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,077 0.0063% | $1.38 | $5,628 | +5.60% | |
| 2023-12-20 | Sale | Ogden Christopher | SVP, Finance and Accounting | 1,990 0.0031% | $1.38 | $2,747 | +5.60% |
Insider Historical Profitability
| McCarthy Sean A. | CEO | 995195 0.6317% | $2.02M | 0 | 35 | |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 248636 0.1578% | $504,731.08 | 0 | 5 | |
| Ogden Christopher | Chief Financial Officer | 201026 0.1276% | $408,082.78 | 0 | 5 | |
| Chu Yu-Waye | Chief Medical Officer | 135725 0.0862% | $275,521.75 | 0 | 1 | |
| ROWLAND LLOYD A | General Counsel | 120594 0.0765% | $244,805.82 | 1 | 7 | <0.0001% |
| Landau Jeffrey B | Chief Business Officer | 119056 0.0756% | $241,683.68 | 0 | 6 | |
| THIRD ROCK VENTURES LP | 10 percent owner | 5170348 3.2818% | $10.5M | 0 | 2 | |
| Canaan IX L.P. | director | 3644381 2.3132% | $7.4M | 0 | 29 | |
| SHANNON TIMOTHY M | director | 3244381 2.0593% | $6.59M | 0 | 29 | |
| Flynn James E | 10 percent owner | 671024 0.4259% | $1.36M | 1 | 0 | <0.0001% |
| GLUCK FREDERICK W | director | 271643 0.1724% | $551,435.29 | 1 | 8 | <0.0001% |
| Peterson Amy C. | EVP, Chief Development Officer | 58433 0.0371% | $118,618.99 | 0 | 2 | |
| Campoy Carlos | Chief Financial Officer | 38224 0.0243% | $77,594.72 | 0 | 2 | |
| HANNAH ALISON L. | Chief Medical Officer | 31898 0.0202% | $64,752.94 | 0 | 1 | |
| STARR KEVIN P | 10 percent owner | 31419 0.0199% | $63,780.57 | 0 | 1 | |
| HUMPHREY RACHEL | Chief Medical Officer | 30234 0.0192% | $61,375.02 | 0 | 2 | |
| TEPPER ROBERT I | 10 percent owner | 29516 0.0187% | $59,917.48 | 0 | 3 | |
| Kavanaugh William Michael | CSO, Head Res.&Non-Clin. Dev. | 13917 0.0088% | $28,251.51 | 1 | 1 | <0.0001% |
| Goeltz II Robert C. | Chief Financial Officer | 9789 0.0062% | $19,871.67 | 0 | 1 | |
| RAY DEBANJAN | Chief Financial Officer | 5928 0.0038% | $12,033.84 | 0 | 19 | |
| Jones Elaine V | director | 5142 0.0033% | $10,438.26 | 1 | 0 | +0.98% |
| LADD CYNTHIA J | Senior VP and General Counsel | 3000 0.0019% | $6,090.00 | 1 | 0 | <0.0001% |
| Exter Neil | director | 0 0% | $0 | 0 | 2 |
Historical Insider Profitability vs. Competitors
$21,575,910 | 89 | 3.57% | $305.3M | |
$69,130,029 | 69 | 25.63% | $322.99M | |
$109,415,500 | 33 | 18.13% | $300.55M | |
$18,554,304 | 31 | -11.72% | $330.73M | |
$73,500,193 | 28 | 42.95% | $307.04M | |
$3,668,031 | 23 | 1.97% | $297.68M | |
$24,857,912 | 21 | -35.40% | $330.56M | |
$46,442,839 | 15 | -20.05% | $347.47M | |
$65,355,913 | 13 | -3.42% | $299.1M | |
$1,037,470 | 13 | 78.00% | $315.95M | |
$133,369,382 | 10 | 5.02% | $322.26M | |
$1,580,951 | 9 | -14.18% | $337.05M | |
$157,484,277 | 8 | 28.67% | $298.92M | |
$4,706,376 | 8 | 42.30% | $302.35M | |
CytomX Therapeutics, Inc. (CTMX) | $15,652,720 | 6 | -4.77% | $319.81M |
$19,420,853 | 5 | 4.35% | $336.25M | |
$602,180 | 4 | -26.17% | $339.11M | |
$58,352 | 4 | -43.78% | $303.52M | |
$8 | 2 | 28.83% | $348.16M |
CTMX Institutional Investors: Active Positions
| Increased Positions | 37 | +48.68% | 8M | +16.14% |
| Decreased Positions | 31 | -40.79% | 11M | -22.53% |
| New Positions | 11 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 9M | Sold Out |
| Total Postitions | 82 | +7.89% | 47M | -6.39% |
CTMX Ownership Change vs Market
Institutional Investor Ownership
| Tang Capital Management Llc | $5,864.00 | 9.14% | 7.31M | -500,000 | -6.4% | 2024-12-31 |
| Bvf Inc/Il | $4,193.00 | 6.54% | 5.23M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $4,140.00 | 6.45% | 5.16M | 0 | 0% | 2024-12-31 |
| Prosight Management, Lp | $3,132.00 | 4.88% | 3.9M | +882,891 | +29.21% | 2024-12-31 |
| Millennium Management Llc | $2,583.00 | 4.03% | 3.22M | +660,756 | +25.81% | 2024-12-31 |
| Acadian Asset Management Llc | $2,516.00 | 3.92% | 3.14M | +36,052 | +1.16% | 2024-12-31 |
| Point72 Asset Management, L.P. | $2,125.00 | 3.31% | 2.65M | +3M | New | 2024-12-31 |
| Jacobs Levy Equity Management, Inc | $1,241.00 | 1.93% | 1.55M | +23,139 | +1.52% | 2024-12-31 |
| Schonfeld Strategic Advisors Llc | $1,107.00 | 1.73% | 1.38M | +169,000 | +13.95% | 2024-12-31 |
| Renaissance Technologies Llc | $1,080.00 | 1.68% | 1.35M | +331,800 | +32.69% | 2024-12-31 |